Immucell (ICCC) Equity Average (2016 - 2025)
Immucell (ICCC) has disclosed Equity Average for 16 consecutive years, with $29.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average rose 19.65% year-over-year to $29.8 million, compared with a TTM value of $29.8 million through Sep 2025, up 19.65%, and an annual FY2024 reading of $26.3 million, down 5.17% over the prior year.
- Equity Average was $29.8 million for Q3 2025 at Immucell, up from $29.4 million in the prior quarter.
- Across five years, Equity Average topped out at $32.9 million in Q1 2022 and bottomed at $24.0 million in Q2 2024.
- Average Equity Average over 5 years is $28.9 million, with a median of $29.3 million recorded in 2023.
- The sharpest move saw Equity Average decreased 18.21% in 2023, then rose 22.39% in 2025.
- Year by year, Equity Average stood at $32.5 million in 2021, then dropped by 4.11% to $31.2 million in 2022, then fell by 18.21% to $25.5 million in 2023, then increased by 5.73% to $27.0 million in 2024, then rose by 10.64% to $29.8 million in 2025.
- Business Quant data shows Equity Average for ICCC at $29.8 million in Q3 2025, $29.4 million in Q2 2025, and $28.3 million in Q1 2025.